Animal studies by Sato et al demonstrated that MEF2C was able to act as a negative regulator of p53-responsive elements, and that p53 had an inhibitory effect on defective osteosarcoma cell lines.[33,34] This suggests a regulatory interplay between MEF2C and p53 in driving OS progression. Here, TP53 is linked to osteosarcoma.